Investing.com-- AbbVie is expected to face investor scrutiny over the durability of its immunology franchise and the strength of newer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE